NCT04906941 - Assessment of the Impact of Gadolinium Injection on the Measurement of the QSM Signal | Crick

Overview

Patients meeting the inclusion and non-inclusion criteria will be offered to participate in the study. If they agree, they will perform an MRI without injection to obtain the QSM then perform the MRI with injection that was prescribed to them as part of the care, then they will perform a second time the MRI without injection to obtain the QSM. They will also answer a short questionnaire documenting their previous exposure to gadolinium.

Study Type

OBSERVATIONAL

Enrollment

73

Conditions

White Matter Disease

Interventions

MRIDEVICE

SWI QSM 1.0iso 8 echos sequence performed before and after the injected MRI prescribed as part of the treatment. \* Sense 2 \* 2: 9min33s

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients over 18 years old * with an inflammatory CNS pathology * to benefit as part of care from an MRI with injection of gadolinium * consent to participate in the study * beneficiary of a social protection scheme Exclusion Criteria: * pregnant or breastfeeding woman * patient benefiting from a legal protection measure * Patient having performed more than 3 MRI exams with gadolinium injection during his life Secondary exclusion criteria : * motion artifact not allowing image interpretation * patient who has not completed one of the following sequences: T1 anatomical, FLAIR, or QSM pre-gadolinium injection. Secondarily excluded patients will be replaced up to a maximum of 25 patients.

Locations (1)

Hhopital fondation adolphe de rothschild

Paris, Paris, France

Outcomes

Primary Outcomes

mean of the delta observed between the QSM of the white matter before and after injection of gadolinium

Time frame: 1 DAY